

# Paul Nankivell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9414405/publications.pdf>

Version: 2024-02-01

40  
papers

1,652  
citations

566801

15  
h-index

301761

39  
g-index

43  
all docs

43  
docs citations

43  
times ranked

3670  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 51-60.	6.3	697
2	Elective Cancer Surgery in COVID-19â€“Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 66-78.	0.8	165
3	Tympanoplasty for Chronic Tympanic Membrane Perforation in Children. <i>Otology and Neurotology</i> , 2015, 36, 796-804.	0.7	106
4	Delaying surgery for patients with a previous SARS-CoV-2 infection. <i>British Journal of Surgery</i> , 2020, 107, e601-e602.	0.1	96
5	Safety and 30-day outcomes of tracheostomy for COVID-19: a prospective observational cohort study. <i>British Journal of Anaesthesia</i> , 2020, 125, 872-879.	1.5	96
6	The binary oral dysplasia grading system: validity testing and suggested improvement. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 115, 87-94.	0.2	63
7	Oral Dysplasia: Biomarkers, Treatment, and Follow-up. <i>Current Oncology Reports</i> , 2011, 13, 145-152.	1.8	45
8	Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. <i>Oral Oncology</i> , 2019, 88, 145-152.	0.8	40
9	Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2018, 40, 1598-1604.	0.9	34
10	Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects. <i>Cancers</i> , 2019, 11, 1115.	1.7	28
11	Biomarkers in laryngeal dysplasia: A systematic review. <i>Head and Neck</i> , 2011, 33, 1170-1176.	0.9	26
12	Re-operative thyroid surgery: a 20-year prospective cohort study at a tertiary referral centre. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 1503-1508.	0.8	26
13	Tetraspanins CD9 and CD151, epidermal growth factor receptor and cyclooxygenase-2 expression predict malignant progression in oral epithelial dysplasia. <i>British Journal of Cancer</i> , 2013, 109, 2864-2874.	2.9	24
14	The impact of nodal status in major salivary gland carcinoma: A multicenter experience and proposal of a novel N-classification. <i>Oral Oncology</i> , 2021, 112, 105076.	0.8	20
15	A digital score of tumourâ€“associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma. <i>Journal of Pathology</i> , 2022, 256, 174-185.	2.1	20
16	Definition of locally recurrent head and neck squamous cell carcinoma: a systematic review and proposal for the Odenseâ€“Birmingham definition. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 1593-1599.	0.8	19
17	Factors affecting prognosis in locoregional recurrence of oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2019, 48, 206-213.	1.4	14
18	Pretreatment High <sc>MCV</sc> as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer. <i>Laryngoscope</i> , 2021, 131, E836-E845.	1.1	14

#	ARTICLE	IF	CITATIONS
19	Investigation of p16 <sup>INK4a</sup> as a prognostic biomarker in oral epithelial dysplasia. <i>Journal of Oral Pathology and Medicine</i> , 2014, 43, 245-249.	1.4	13
20	The diagnostic value of cytology in parotid Warthin's tumors: international multicenter series. <i>Head and Neck</i> , 2020, 42, 522-529.	0.9	13
21	Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113854.	6.6	12
22	Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA. <i>Epigenomes</i> , 2021, 5, 6.	0.8	10
23	Surveillance of HPV-Positive Head and Neck Squamous Cell Carcinoma with Circulating and Salivary DNA Biomarkers. <i>Critical Reviews in Oncogenesis</i> , 2018, 23, 235-245.	0.2	8
24	Do corticosteroids improve outcomes in peritonsillar abscess?. <i>Laryngoscope</i> , 2015, 125, 537-538.	1.1	7
25	Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8229.	1.8	7
26	Feasibility of recruitment to an oral dysplasia trial in the United Kingdom. <i>Head &amp; Neck Oncology</i> , 2012, 4, 40.	2.3	6
27	Immediate Sample Fixation Increases Circulating Tumour Cell (CTC) Capture and Preserves Phenotype in Head and Neck Squamous Cell Carcinoma: Towards a Standardised Approach to Microfluidic CTC Biomarker Discovery. <i>Cancers</i> , 2021, 13, 5519.	1.7	6
28	The diagnostic value of cytology in parotid Warthin's tumors: International multicenter series. <i>Head and Neck</i> , 2020, 42, 2215-2216.	0.9	5
29	The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and neck cancer: An analysis of the PET-NECK trial outcomes, UKCRN portfolio, and Hospital Episode Statistics (HES) in England. <i>Oral Oncology</i> , 2018, 85, 40-43.	0.8	4
30	Patient advocacy in head and neck cancer: Realities, challenges and the role of the multi-disciplinary team. <i>Clinical Otolaryngology</i> , 2020, 45, 437-444.	0.6	4
31	Development and validation of an improved classification and risk stratification system for carotid body tumors: Multinational collaborative cohort study. <i>Head and Neck</i> , 2021, 43, 3448-3458.	0.9	4
32	Prognostic indicators in clinically node-negative malignant primary salivary tumours of the parotid: A multicentre experience. <i>Oral Oncology</i> , 2021, 123, 105577.	0.8	3
33	Exploring the views of patients' and their family about patient-initiated follow-up in head and neck cancer: A mixed methods study. <i>European Journal of Cancer Care</i> , 2022, 31, .	0.7	3
34	The presentation, natural history and outcome of T1 a/b thyroid cancer with regard to new grading systems. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 439-444.	0.8	2
35	Conservative management of oesophageal soft food bolus impaction. <i>The Cochrane Library</i> , 2020, 2020, CD007352.	1.5	2
36	Prioritisation of research topics for head and neck cancer in Africa – Report of the International Collaboration On Improving Cancer outcomes in low and middle income countries – IConIC Africa. <i>Oral Oncology</i> , 2020, 102, 104503.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Differential Expression of Potential Biomarkers of Oral Squamous Cell Carcinoma Development. Head and Neck Pathology, 2021, 15, 1127-1136.	1.3	2
38	Symptom-based remote assessment in post-treatment head and neck cancer surveillance: A prospective national study. Clinical Otolaryngology, 2022, 47, 561-567.	0.6	2
39	COREC Model Information: Can Patients Read What COREC Wants Us to Give Them?. Research Ethics, 2007, 3, 22-23.	0.8	1
40	Civilian Penetrating Neck Trauma at a Level I Trauma Centre: A Five-Year Retrospective Case Note Review. Clinical Otolaryngology, 2021, 47, 44.	0.6	1